secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-123727
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026
--------------------------------------------------------------------------------

- Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.
- Cash and equivalents $199.0M as of Sep 30, 2024; expected cash runway into 2026.
- Appointed Dhaval Patel as Chief Scientific Officer; expanding focus on type 1 diabetes and B-cell autoimmune diseases.
- Enrolling patients in three studies: UP421 (type 1 diabetes), GLEAM (SC291 autoimmune), VIVID (SC262 oncology); data expected in 2024/2025.
- Non-GAAP operating cash burn $153.1M for first nine months 2024; strategic repositioning may increase 2024 burn above prior guidance of <$200M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/0000950170-24-123727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/sana-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer